Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT07493993 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

ESCC

Interventions

DRUG: lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital